/HAVLF
HAVLF Stock - HAVN Life Sciences Inc.
Healthcare|BiotechnologyOTC
$0.00+0.00%
+$0.00 (+0.00%) • Dec 19
76
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.84
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for HAVLF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.00 – $0.00
TARGET (TP)$0.00
STOP LOSS$0.00
RISK/REWARD1:-1.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.34
52W High$0.01
52W Low$0.00
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2022 | FY2021 | FY2020 |
|---|---|---|---|
| Revenue | $276,473 | N/A | N/A |
| Gross Profit | $89,693 | $-4,604,536 | N/A |
| Gross Margin | 32.4% | N/A | N/A |
| Operating Income | $-9,810,466 | $-30,353,138 | $-40,576 |
| Net Income | $-22,443,548 | $-30,380,633 | $-40,576 |
| Net Margin | -8117.8% | N/A | N/A |
| EPS | $-5.25 | $-8.47 | $-0.02 |
Company Overview
HAVN Life Sciences Inc., a biotechnology company, engages in the research and development of psychopharmacological products from plants and fungi. The Company also focuses on developing methodologies for the standardize and quality-controlled extraction of psychoactive compounds from plants and fungi, including Psilocybe spp. mushrooms; and the genera directive compounds, such as psilocybin, psilocin, and baeocystin, as well as the development of natural health care products from non-regulated compounds. The company was incorporated in 2020 and is headquartered in Richmond, Canada.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
HAVLFBeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-0.05
Q1 2023
EPS Surprise History
Q2 21
No data
Q3 21
No data
Q4 21
No data
Q1 22
No data
Q2 22
No data
Q3 22
No data
Q4 22
No data
Q1 23
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2024 | Aug 2, 2024 | — | — | — | — |
Q2 2024 | Apr 19, 2024 | — | — | — | — |
Q1 2024 | Feb 12, 2024 | — | — | — | — |
Q4 2023 | Dec 29, 2023 | — | — | — | — |
Q3 2023 | Aug 2, 2023 | — | — | — | — |
Q3 2023 | Aug 2, 2023 | — | — | — | — |
Q1 2023 | Jan 31, 2023 | — | $-0.05 | — | — |
Q4 2022 | Oct 31, 2022 | — | $-0.30 | — | — |
Q3 2022 | Jul 31, 2022 | — | $-21.08 | — | — |
Q2 2022 | Apr 30, 2022 | — | $-1.85 | — | — |
Q1 2022 | Jan 31, 2022 | — | $-0.41 | — | — |
Q4 2021 | Oct 31, 2021 | — | $-1.15 | — | — |
Q3 2021 | Jul 31, 2021 | — | $-18.10 | — | — |
Q2 2021 | Apr 30, 2021 | — | $-2.49 | — | — |
Q1 2021 | Jan 31, 2021 | — | $-4.02 | — | — |
Q4 2020 | Oct 31, 2020 | — | $-2.52 | — | — |
Q3 2020 | Jul 31, 2020 | — | $-0.27 | — | — |
Latest News
Loading news...
Frequently Asked Questions about HAVLF
What is HAVLF's current stock price?
HAVN Life Sciences Inc. (HAVLF) is currently trading at $0.00 per share. The stock has moved +0.00% today.
What is the analyst price target for HAVLF?
No analyst price targets are currently available for this stock.
What sector is HAVN Life Sciences Inc. in?
HAVN Life Sciences Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the OTC exchange.
What is HAVLF's market cap?
HAVN Life Sciences Inc. has a market capitalization of $0.00 billion, making it a small-cap company.
Does HAVLF pay dividends?
No, HAVN Life Sciences Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorADXS
Ayala Pharmaceuticals, Inc.
$0.15
Mkt Cap: $0.0B
ARUXF
Acrux Limited
$0.01
Mkt Cap: $0.0B
AXIM
AXIM Biotechnologies, Inc.
$0.02
Mkt Cap: $0.0B
NRPR
Resilient Healthcare Corp
$0.05
Mkt Cap: $0.0B
PKTX
ProtoKinetix, Incorporated
$0.01
Mkt Cap: $0.0B
REPCF
RepliCel Life Sciences Inc.
$0.00
Mkt Cap: $0.0B
RGBP
Regen BioPharma, Inc.
$0.01
Mkt Cap: $0.0B
SIGY
Sigyn Therapeutics, Inc.
$1.71
Mkt Cap: $0.0B
TLIS
Talis Biomedical Corporation
$2.84
Mkt Cap: $0.0B
ZLDAF
Zelira Therapeutics Limited
$0.23
Mkt Cap: $0.0B
Explore stocks similar to HAVLF for comparison